

Figure e-2. MRZ and herpesvirus-specific antibodies in CSF and serum before (V0) and after 12 months of natalizumab treatment (V12). Serum and CSF levels of antibodies reactive to **(A)** measles virus, **(B)** rubella virus, **(C)** VZV, **(D)** CMV, **(E)** HSV-1, **(F)** HSV-2, **(G)** EBV-VCA and **(H)** EBV-EBNA-1 are depicted in arbitrary units (AU). Intrathecal production of the respective antibodies is indicated by CSF/serum antigen-specific antibody index (CAI_{Measles}, CAI_{Rubella}, CAI_{VZV}, CAI_{HSV-1}, CAI_{HSV-2}, CAI_{CMV}, CAI_{EBV-VCA}, CAI_{EBNA-1}). The p-value is shown in case of statistically significant differences. Statistics: Wilcoxon-matched pairs test (A-H).

